How we do it
Our team of experts facilitates the whole process of accessing biospecimens
Our team of PhD-qualified project leaders has expertise in biobanking, biospecimen assays, and biomarker development. Scientists interacting with scientists, which fosters insightful discussions and time savings while defining project specifications.
Our multilingual team of scientists will facilitate the process of accessing biospecimens in various fields including oncology, infectious diseases, CNS diseases among others.
We carefully assess your needs to meet your specific requirements for biospecimen collections and associated medical data
We locate the right provider and proceed with a timely and efficient feasibility study
We discuss Biobank Options with the End-User
A Teleconference between the End-User and the Biobank may be organized to discuss any scientific or technical details
We ensure Samples and Associated Data arrive at the End-User's lab in due time
Our worldwide network of partnerships with academic, hospital and clinical sources specialized in various medical fields supported by a proprietary database can successfully take on challenging requests.
Timing in biospecimen procurement is a key factor in the choice of a biospecimen provider. Delays generated by the contractual process between these parties can jeopardize an entire research project.
Over 150 leading academic, hospital, and clinical biospecimen sources have entered into a Master Service Agreement (MSA) with Trans-Hit Bio and agreed upon its umbrella Material Transfer Agreement (MTA) template. Our templates have already been reviewed and accepted by the legal departments of many biopharmaceutical companies, which has saved them months in administrative work.
Trans-Hit Bio removes the blindfold!
Industry partners are informed of the sample’s source and our partnered biobanks are informed of the end-users. Our unique model enables us to:
Note: Samples are always shipped directly from the Biospecimen Provider to the Industry Researcher.